Other O
tumor B
types O
found O
in O
BRCA1 O
mutation O
/ O
haplotype O
carriers O
included O
prostatic B
, I
pancreas I
, I
skin I
, I
and I
lung I
cancer I
, O
a O
malignant B
melanoma I
, O
an O
oligodendroglioma B
, O
and O
a O
carcinosarcoma B
. O

The O
von B
Hippel I
- I
Lindau I
( I
VHL I
) I
disease I
product O
is O
thought O
to O
down O
- O
regulate O
transcription O
by O
antagonizing O
elongin O
- O
enhanced O
transcriptional O
elongation O
. O

In O
most O
people O
with O
red O
- O
blood O
- O
cell O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency I
, O
the O
enzyme O
- O
deficient O
phenotype O
is O
only O
moderately O
expressed O
in O
nucleated O
cells O
. O

Complete B
hypoxanthine I
- I
guanine I
phosphoribosyl I
- I
transferase I
( I
HPRT I
) I
deficiency I
in O
humans O
results O
in O
the O
Lesch B
- I
Nyhan I
syndrome I
which O
is O
characterized O
, O
among O
other O
features O
, O
by O
compulsive O
self O
- O
injurious O
behavior O
. O

Twenty O
microsatellite O
markers O
in O
the O
HRPT2 O
region O
were O
typed O
, O
in O
addition O
to O
markers O
in O
the O
multiple B
endocrine I
neoplasia I
( I
MEN I
) I
types I
1 I
and I
2 I
regions O
at O
11q13 O
and O
10q11 O
. O

The O
von B
Hippel I
- I
Lindau I
tumor I
suppressor O
gene O
( O
VHL O
) O
has O
a O
critical O
role O
in O
the O
pathogenesis O
of O
clear B
- I
cell I
renal I
cell I
carcinoma I
( O
RCC B
) O
, O
as O
VHL O
mutations O
have O
been O
found O
in O
both O
von B
Hippel I
- I
Lindau I
disease I
- I
associated I
and I
sporadic I
RCCs I
. O

Recent O
studies O
suggest O
that O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
mRNA O
is O
upregulated O
in O
RCC B
- I
and I
von I
Hippel I
- I
Lindau I
disease I
- I
associated I
tumors I
. O

